Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Nov;40(11):2622–2625. doi: 10.1093/gao/9781884446054.article.t049341

Effect of fluconazole on viability of Candida albicans over extended periods of time.

P G Sohnle 1, B L Hahn 1, M D Erdmann 1
PMCID: PMC163587  PMID: 8913476

Abstract

The treatment of chronic mycoses may expose the infecting organisms to antimicrobial agents for extended periods of time. It is possible that an azole antifungal drug such as fluconazole, with primarily fungistatic activity in standard in vitro susceptibility tests, might be able to damage the fungal cells and reduce their viability over prolonged incubations under nonproliferating conditions. To test this possibility, Candida albicans yeast cells were exposed to various concentrations of fluconazole in RPMI 1640 tissue culture medium for 4 h at 37 degrees C, washed free of the drug, and then incubated at 37 degrees C for a 28-day period; enumeration of the remaining CFU at various times during this period revealed no increased loss of viability for the fluconazole-exposed organisms. However, when fluconazole was added to the organisms maintained in distilled water (with or without pretreatment with the drug), a marked reduction of viability was found. At 14 days of incubation with two strains of C. albicans, negative cultures were found for 7 of 10 and 10 of 11 samples, respectively, containing 1.0 microgram of fluconazole per ml versus 0 of 10 and 1 of 11 control samples (P of < 0.01 and 0.001, respectively). The effect of fluconazole on fungal viability under these conditions became noticeable at approximately 7 days and was greater when the samples were incubated at 37 degrees C rather than 25 degrees C. These findings suggest that fluconazole may have fungicidal effects on fungal cells during prolonged exposures under conditions in which the organisms are prevented from proliferating by lack of nutrients.

Full Text

The Full Text of this article is available as a PDF (199.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anaissie E., Bodey G. P., Kantarjian H., David C., Barnett K., Bow E., Defelice R., Downs N., File T., Karam G. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med. 1991 Aug;91(2):142–150. doi: 10.1016/0002-9343(91)90006-j. [DOI] [PubMed] [Google Scholar]
  2. Bodey G. P. Azole antifungal agents. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S161–S169. doi: 10.1093/clinids/14.supplement_1.s161. [DOI] [PubMed] [Google Scholar]
  3. Brass C., Galgiani J. N., Campbell S. C., Stevens D. A. Therapy of disseminated or pulmonary coccidioidomycosis with ketoconazole. Rev Infect Dis. 1980 Jul-Aug;2(4):656–660. doi: 10.1093/clinids/2.4.656. [DOI] [PubMed] [Google Scholar]
  4. De Nollin S., Van Belle H., Goossens F., Thone F., Borgers M. Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrob Agents Chemother. 1977 Mar;11(3):500–513. doi: 10.1128/aac.11.3.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dismukes W. E., Bradsher R. W., Jr, Cloud G. C., Kauffman C. A., Chapman S. W., George R. B., Stevens D. A., Girard W. M., Saag M. S., Bowles-Patton C. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med. 1992 Nov;93(5):489–497. doi: 10.1016/0002-9343(92)90575-v. [DOI] [PubMed] [Google Scholar]
  6. Durack D. T., Beeson P. B. Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations. Br J Exp Pathol. 1972 Feb;53(1):50–53. [PMC free article] [PubMed] [Google Scholar]
  7. Galgiani J. N. Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S272–S275. doi: 10.1093/clinids/12.supplement_3.s272. [DOI] [PubMed] [Google Scholar]
  8. Graybill J. R., Lundberg D., Donovan W., Levine H. B., Rodriguez M. D., Drutz D. J. Treatment of coccidioidomycosis with ketoconazole: clinical and laboratory studies of 18 patients. Rev Infect Dis. 1980 Jul-Aug;2(4):661–673. doi: 10.1093/clinids/2.4.661. [DOI] [PubMed] [Google Scholar]
  9. Hughes C. E., Beggs W. H. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother. 1987 Feb;19(2):171–174. doi: 10.1093/jac/19.2.171. [DOI] [PubMed] [Google Scholar]
  10. Isaacson D. M., Tolman E. L., Tobia A. J., Rosenthale M. E., McGuire J. L., Vanden Bossche H., Janssen P. A. Selective inhibition of 14 alpha-desmethyl sterol synthesis in Candida albicans by terconazole, a new triazole antimycotic. J Antimicrob Chemother. 1988 Mar;21(3):333–343. doi: 10.1093/jac/21.3.333. [DOI] [PubMed] [Google Scholar]
  11. Kauffman C. A., Bradley S. F., Ross S. C., Weber D. R. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med. 1991 Aug;91(2):137–141. doi: 10.1016/0002-9343(91)90005-i. [DOI] [PubMed] [Google Scholar]
  12. Mikami Y., Scalarone G. M., Kurita N., Yazawa K., Uno J., Miyaji M. Synergistic postantifungal effect of flucytosine and fluconazole on Candida albicans. J Med Vet Mycol. 1992;30(3):197–206. doi: 10.1080/02681219280000261. [DOI] [PubMed] [Google Scholar]
  13. Rogers T. E., Galgiani J. N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 1986 Sep;30(3):418–422. doi: 10.1128/aac.30.3.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sheehan D. J., Espinel-Ingroff A., Moore L. S., Webb C. D. Antifungal susceptibility testing of yeasts: a brief overview. Clin Infect Dis. 1993 Nov;17 (Suppl 2):S494–S500. doi: 10.1093/clinids/17.supplement_2.s494. [DOI] [PubMed] [Google Scholar]
  15. Sohnle P. G., Hahn B. L. Inhibition of pseudohyphal growth as a neutrophil-mediated host defense mechanism against experimental deep Candida albicans infections in mice. J Lab Clin Med. 1993 Feb;121(2):235–243. [PubMed] [Google Scholar]
  16. Troke P. F., Andrews R. J., Pye G. W., Richardson K. Fluconazole and other azoles: translation of in vitro activity to in vivo and clinical efficacy. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S276–S280. doi: 10.1093/clinids/12.supplement_3.s276. [DOI] [PubMed] [Google Scholar]
  17. Van den Bossche H. Biochemical effects of miconazole on fungi. I. Effects on the uptake and or utilization of purines, pyrimidines, nucleosides, amino acids and glucose by Candida albicans. Biochem Pharmacol. 1974 Feb 15;23(4):887–899. doi: 10.1016/0006-2952(74)90220-2. [DOI] [PubMed] [Google Scholar]
  18. van den Bossche H., Willemsens G., Cools W., Lauwers W. F., Le Jeune L. Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans. Chem Biol Interact. 1978 Apr;21(1):59–78. doi: 10.1016/0009-2797(78)90068-6. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES